OpenBilldrug price receipt

NADAC week of 2026-10-14

DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET

For 30 tablets

Pharmacies pay

$13.82 filed

30 × $0.46063 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$314.36 filed

30 × $10.47878 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

22.7× estimated

These two figures may not measure the same thing

At 22.7×, the Medicare figure is 20 or more times what pharmacies pay. A gap that large means the two figures may not describe the same unit or product, or the price may have changed between their dates; check what each one covers before relying on the multiple.

Part D averages every strength and form sold under “Dapagliflozin-Metformin ER” / “Dapaglifloz Propaned/Metformin” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$20.89 estimated

$13.82 + $2.07 (15%) + $5.00 fee per fill = $20.89

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as dapagliflozin and metformin hydrochloride.

FDA gives its dosage form as “tablet, extended release” and “tablet, film coated, extended release” and its route as oral.

FDA lists 7 labelers (the companies named on the label) for its NDCs, among them Macleods Pharmaceuticals Limited, Aurobindo Pharma Limited and Sun Pharmaceutical Industries, Inc.

FDA lists it under 2 Established Pharmacologic Classes: Biguanide and Sodium-Glucose Cotransporter 2 Inhibitor.

The NADAC file of 2026-10-14 prices it under 7 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $13.82 for 30 tablets (30 × $0.46063 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

The 7 labelers

LabelerNDCsPharmacies pay per unit
Ascend Laboratories, LLC1$0.46063 per EA filed
Aurobindo Pharma Limited1$0.46063 per EA filed
Lupin Pharmaceuticals, Inc.1$0.46063 per EA filed
Macleods Pharmaceuticals Limited1$0.46063 per EA filed
Novadoz Pharmaceuticals LLC1$0.46063 per EA filed
Prasco Laboratories1$0.46063 per EA filed
Sun Pharmaceutical Industries, Inc.1$0.46063 per EA filed
All 7 NDCs, with labeler and price
  • 33342-0408-09 · Macleods Pharmaceuticals Limited · $0.46063 per EA · eff. 2026-09-23 filed
  • 59651-0155-60 · Aurobindo Pharma Limited · $0.46063 per EA · eff. 2026-09-23 filed
  • 63304-0026-62 · Sun Pharmaceutical Industries, Inc. · $0.46063 per EA · eff. 2026-09-23 filed
  • 66993-0361-60 · Prasco Laboratories · $0.46063 per EA · eff. 2026-09-23 filed
  • 67877-0620-60 · Ascend Laboratories, LLC · $0.46063 per EA · eff. 2026-09-23 filed
  • 70748-0102-07 · Lupin Pharmaceuticals, Inc. · $0.46063 per EA · eff. 2026-09-23 filed
  • 72205-0435-03 · Novadoz Pharmaceuticals LLC · $0.46063 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

8 other products in the NADAC file share the FDA nonproprietary name dapagliflozin and metformin hydrochloride with DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET this page
generic · tablet, extended release / tablet, film coated, extended release
$0.46063 per EA filed
eff. 2026-09-23
$10.47878 per EA filed
Part D 2024 average
DAPAGLIFLOZIN-METFORMIN ER 5-500 MG TABLET
generic · tablet, extended release / tablet, film coated, extended release
$0.70725 per EA filed
eff. 2026-09-23
$10.47878 per EA filed
Part D 2024 average
DAPAGLIFLOZIN-METFORMIN ER 10-1,000 MG TABLET
generic · tablet, extended release / tablet, film coated, extended release
$0.71952 per EA filed
eff. 2026-09-23
$10.47878 per EA filed
Part D 2024 average
DAPAGLIFLOZIN-METFORMIN ER 10-500 MG TABLET
generic · tablet, extended release / tablet, film coated, extended release
$0.80198 per EA filed
eff. 2026-09-23
$10.47878 per EA filed
Part D 2024 average
XIGDUO XR 2.5 MG-1,000 MG TAB
brand · tablet, film coated, extended release
$9.60825 per EA filed
eff. 2026-09-23
$13.6073 per EA filed
Part D 2024 average
XIGDUO XR 5 MG-1,000 MG TABLET
brand · tablet, film coated, extended release
$9.59236 per EA filed
eff. 2026-09-23
$13.6073 per EA filed
Part D 2024 average
XIGDUO XR 5 MG-500 MG TABLET
brand · tablet, film coated, extended release
$19.18159 per EA filed
eff. 2026-09-23
$13.6073 per EA filed
Part D 2024 average
XIGDUO XR 10 MG-1,000 MG TAB
brand · tablet, film coated, extended release
$19.20443 per EA filed
eff. 2026-09-23
$13.6073 per EA filed
Part D 2024 average
XIGDUO XR 10 MG-500 MG TABLET
brand · tablet, film coated, extended release
$19.2391 per EA filed
eff. 2026-09-23
$13.6073 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 7 NDCs’ NADAC prices is $0.46063 per EA filed.

Of the 71 other products in FDA’s Biguanide class priced per EA, 55 have a higher middle NADAC price and 16 a lower one. The one in the middle is SYNJARDY XR 5-1,000 MG TABLET, at $5.61111 per EA filed (eff. 2026-09-23).

Of the 39 other products in FDA’s Sodium-Glucose Cotransporter 2 Inhibitor class priced per EA, 37 have a higher middle NADAC price and 2 a lower one. The one in the middle is XIGDUO XR 2.5 MG-1,000 MG TAB, at $9.60825 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $314.36 for 30 tablets, at an average of $10.47878 per EA in 2024 (2024-01-01 to 2024-12-31) for “Dapagliflozin-Metformin ER” and “Dapaglifloz Propaned/Metformin”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 12,164 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for DAPAGLIFLOZIN-METFORMIN ER 5-1,000 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Dapagliflozin-Metformin ER / Dapaglifloz Propaned/Metformin: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.